Inhibrx Biosciences Reports Q1 2025 Results: Net Loss Narrows to $43.3M, EPS Improves to $2.80

Reuters
15 May
<a href="https://laohu8.com/S/INBX">Inhibrx Biosciences</a> Reports Q1 2025 Results: Net Loss Narrows to $43.<a href="https://laohu8.com/S/MMM">3M</a>, EPS Improves to $2.80

Inhibrx Biosciences, Inc. has announced its financial results for the first quarter of 2025, revealing a net loss of $43.3 million, a decrease from the net loss of $78.7 million in the same period of 2024. The company's cash and cash equivalents increased to $216.5 million as of March 31, 2025, up from $152.6 million at the end of 2024. This increase was primarily attributed to the receipt of $100 million in gross principal under a loan agreement with Oxford Finance LLC. Research and development expenses for the quarter decreased to $36.9 million from $63.9 million in the first quarter of 2024, largely due to reduced clinical trial and contract manufacturing expenses following the spin-off of the INBRX-101 program. General and administrative expenses also fell to $6.0 million from $10.0 million, mainly due to a decrease in non-cash stock option expenses and lower professional service expenses after the spin-off transaction. Inhibrx continues to focus on its two ongoing clinical trials, with data readouts expected within the year. Notably, data from the registration-enabling Phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma is anticipated in the third quarter of 2025, and interim data from the Phase 1/2 trial in checkpoint inhibitor refractory or relapsed non-small cell lung cancer is expected in the fourth quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA88190) on May 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10